Although the decrease in IL-8 secreted from cancer cells by the antiangiogenic agent sunitinib was observed in a xenograft model of renal cell carcinoma53, no other studies have followed serum levels of IL-8 during targeted therapy in clinical samples. Here, CXCL8 is linked to cancer.